Razel-F10 Forte Tablet is a formulation that combines two medications aimed at reducing lipid levels in the body. It specifically targets cholesterol and triglycerides in the bloodstream, particularly when dietary changes alone, such as implementing a low-fat diet, have proven inadequate. The primary goal of this medication is to lower the risk of developing cardiovascular diseases. Patients can take Razel-F10 Forte either during meals or on an empty stomach, and it is advisable to take it consistently at the same time each day to foster adherence. The dosing will be tailored by a healthcare provider based on the individual’s lipid levels and their overall response to the treatment. Many individuals with elevated cholesterol or triglycerides may not experience noticeable symptoms, but discontinuing the medication could lead to an escalation in lipid levels, increasing the risk of serious conditions such as heart disease and stroke. Regular monitoring of cholesterol and triglyceride levels is essential. This medication is part of a broader treatment strategy that should include maintaining a low-fat diet, engaging in regular physical activity, quitting smoking, moderating alcohol consumption, and managing weight. While taking this medication, it is generally acceptable to maintain a regular diet, although it is prudent to limit high-fat food consumption. Adverse effects such as nausea, abdominal discomfort, constipation, headaches, excessive gas, and muscle pain may occur but are typically mild and temporary. Should these side effects persist or if any serious symptoms like jaundice, unusual bleeding, or severe muscle pain arise, it is important to consult a healthcare professional. Regular liver function tests may be recommended during treatment. Individuals with existing liver issues or other health concerns should inform their healthcare provider before starting this medication.
-15%

RAZEL F 10 FORTE
Original price was: ₹277.30.₹236.60Current price is: ₹236.60.
Add to cart
Buy Now

Reviews
There are no reviews yet.